Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

Circulating cell free tumour DNA (ctDNA) maintains the same genomic alterations that are
present in the corresponding tumour, thereby allowing for quantitative and qualitative real …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Purpose: We investigated whether detection of ctDNA after resection of colorectal cancer
identifies the patients with the highest risk of relapse and, furthermore, whether longitudinal …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

Background Early indicators of treatment response in metastatic colorectal cancer (mCRC)
could conceivably be used to optimize treatment. We explored early changes in circulating …

Substantial improvements have been made in the management of metastatic colorectal
cancer (mCRC) in the last two decades, but disease monitoring remains underdeveloped …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …

Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to
limited biopsy information, impracticality of repeated biopsies, and cancer biomarker …